Skip to content
AnalystLens

IDXX · IDEXX Laboratories

327 filings

IDXX SEC Filings

IDEXX Laboratories - 327 total filings

Filing record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26
Showing 1–50 of 327 filings
10-Q

IDEXX Laboratories Quarterly Report for Q3 Ended Sep 30, 2026

IDEXX Laboratories, Inc. reported strong financial results for the nine months ended September 30, 2026, demonstrating robust revenue growth and improved profitability. Total revenue increased by 11.2% to $3.57 billion, driven primarily by the Companion Animal Group (CAG) segment, which saw a 11.3% revenue increase. This growth was fueled by strong performance in CAG Diagnostics recurring revenue, including IDEXX VetLab consumables and reference laboratory services, supported by higher volumes and pricing. The Water and Livestock, Poultry and Dairy (LPD) segments also contributed positively with revenue growth of 11.3% and 8.7%, respectively. Net income for the nine-month period rose by 15.1% to $934.0 million, and diluted earnings per share increased to $11.75. The company's operational efficiency improved, with gross profit margin expanding by 110 basis points to 63.4%. Significant investments were made in the acquisition of CoVet AI Inc. for approximately $250 million, expanding the company's AI-native software offerings in the veterinary space. Despite increased operating expenses, particularly in general and administrative functions due to acquisitions and technology investments, the company maintained strong income from operations, growing by 14.0% to $1.19 billion.

Nov 2, 2026
8-K

IDEXX Laboratories 8-K Report, Financial Results (Nov 2, 2026)

IDEXX Laboratories, Inc. (IDXX) announced robust financial results for the third quarter ended September 30, 2026. The company reported a 10% increase in revenue on both a reported and organic basis, reaching $1,214 million. This growth was primarily driven by the Companion Animal Group (CAG) segment, which saw an 11% increase in recurring revenue, signaling strong performance in its core diagnostics and consumables offerings. Earnings per diluted share (EPS) also showed significant improvement, rising 18% year-over-year to $4.01. The company demonstrated its confidence in continued success by raising its full-year 2026 guidance for both revenue and EPS. Revenue guidance was increased to a range of $4,741 million to $4,767 million, with the midpoint reflecting a $32 million increase. The EPS outlook was also raised to $14.96 - $15.16. This positive outlook is supported by strong operational execution, benefits from IDEXX's innovations, and strategic acquisitions like CoVet, which is expected to enhance veterinary team productivity.

Nov 2, 2026
8-K

IDEXX Laboratories 8-K Report, Financial Results (Aug 4, 2026)

IDEXX Laboratories reported second quarter 2026 results on August 4, 2026, with revenue of $1,217 million, up 10% as reported and 9% organic. Growth was led by Companion Animal Group (CAG) at 9% and CAG Diagnostics recurring revenue, which rose 11% as reported and 10% organic, with International up 12% organic and U.S. up 10%. Management attributed the strength to volume-driven utilization, net customer expansion, and the growing premium instrument installed base, now 11% larger. Water grew 15% as reported and 13% organic, and LPD grew 11% as reported and 9% organic. Profitability improved meaningfully. Gross margin rose 140 basis points to 64.0%, and operating margin rose 140 basis points to 35.0% as reported (110 basis points comparable). Diluted EPS was $4.27, up 18% as reported and 15% comparable. Note that EPS included $0.14 of share-based compensation tax benefits and $0.06 of currency benefit, so comparable EPS of $4.07 is the cleaner run-rate measure. Operating expenses grew 10%, reflecting investments in commercial capabilities, innovation, and IT. Full-year 2026 guidance was modestly raised. Revenue is now expected at $4,700 million to $4,745 million, a $5 million increase at the midpoint after a $15 million FX headwind. EPS guidance rose to $14.69 to $14.94 from $14.45 to $14.90 at the prior midpoint, though a meaningful portion of the increase reflects share-based compensation benefits rather than operations. Management also reported strong cash generation, with six-month free cash flow of $557 million, and continued share repurchases of about $693 million in the open market during the first half.

Aug 4, 2026
10-Q

IDEXX Laboratories Quarterly Report for Q2 Ended Jun 30, 2026

IDEXX Laboratories, Inc. (IDXX) reported strong financial performance for the six months ended June 30, 2026, demonstrating robust revenue growth and improved profitability. Total revenue increased by 11.8% to $2.36 billion, driven by the Companion Animal Group (CAG) segment, which saw an 11.8% increase in revenue to $2.17 billion. The company's gross profit margin expanded by 120 basis points to 63.7%, reflecting increased volumes, higher realized prices, and operational efficiencies, partially offset by inflationary pressures. Net income rose significantly by 14.9% to $616.9 million, with diluted earnings per share increasing to $7.74. The company maintained a strong liquidity position, with $196.9 million in cash and cash equivalents and $729.2 million in available borrowing capacity under its credit facility. IDEXX continues to focus on strategic investments in growth areas and shareholder returns, evidenced by continued share repurchases. The company's financial outlook remains positive, with continued growth expected across its key segments.

Aug 4, 2026
8-K

IDEXX Laboratories 8-K Report, Bylaw Amendment (May 15, 2026)

IDEXX Laboratories, Inc. (IDXX) filed an 8-K report on May 15, 2026, detailing significant corporate governance changes approved by shareholders at the May 12, 2026 annual meeting. The primary focus is the amendment to the Certificate of Incorporation and By-Laws to declassify the Board of Directors over a three-year period, with all directors to be elected annually starting in 2029. This move enhances shareholder oversight and aligns with modern corporate governance trends, making the board more directly accountable to shareholders. Furthermore, shareholders approved amendments granting a right to call a special meeting to those holding at least 25% of the company's capital stock continuously for at least one year. This provides a critical mechanism for shareholders to address urgent matters outside of the regular annual meeting schedule, increasing their influence and ability to effect change. The report also confirms the ratification of PricewaterhouseCoopers LLP as the independent auditor and the advisory approval of executive compensation, alongside the election of three Class II directors.

May 15, 2026
10-Q

IDEXX Laboratories Quarterly Report for Q1 Ended Mar 31, 2026

IDEXX Laboratories, Inc. reported robust financial performance for the first quarter of 2026, demonstrating significant revenue growth and improved profitability. Total revenue increased by 14.3% year-over-year to $1.14 billion, driven by strong demand across all operating segments, particularly within the Companion Animal Group (CAG). The company achieved a 15.9% increase in gross profit, expanding the gross profit margin by 100 basis points due to recurring revenue growth, operational efficiencies, and effective price realization, despite inflationary pressures. Net income saw a substantial rise of 14.8% to $278.4 million, translating to diluted earnings per share of $3.47, up from $2.96 in the prior year. The company's balance sheet remains solid with $200.5 million in cash and cash equivalents and $718.2 million in available borrowing capacity under its credit facility. Significant stock repurchase activity continued, reflecting a commitment to returning value to shareholders. The company provided a positive outlook, anticipating favorable currency impacts for the remainder of the year.

May 5, 2026
8-K

IDEXX Laboratories 8-K Report, Financial Results (May 5, 2026)

IDEXX Laboratories reported first-quarter 2026 results on May 5, 2026, with revenue of $1,141 million, up 14% as reported and 11% organic. Growth was led by Companion Animal Group (CAG), which grew 15% as reported and 12% organic, and CAG Diagnostics recurring revenue, which grew 14% reported and 11% organic. International recurring revenue grew 21% reported and 12% organic, while U.S. recurring revenue grew 11%, which management says outpaced sector growth. Management attributed the U.S. strength partly to a modest easing of clinical visit pressure and higher diagnostic frequency. Reported diluted EPS was $3.47, up 17% (15% on a comparable basis). Operating margin was 31.8%, up 10 bps as reported and 100 bps on a comparable basis, though operating expenses rose 17% as reported, reflecting commercial, R&D, and software investment. Gross margin improved 90 bps to 63.4%. Management raised 2026 guidance. Revenue is now $4,675-$4,760 million (8.6%-10.6% reported growth, 7.7%-9.7% organic), up about $42 million at the midpoint. The EPS outlook rose to $14.45-$14.90, with the midpoint up $0.13 from operations and $0.05 from FX, partly offset by a $0.05 loss on an equity investment. The reported operating margin outlook is 32.1%-32.5%. Foreign currency is a meaningful tailwind, adding about 0.9% to revenue growth and about $0.27 to EPS for 2026. CEO Jay Mazelsky is transitioning out of the role, with Mike Erickson named as the successor partner; the filing does not detail the leadership change beyond the release's comments. For investors, the quarter shows broad-based double-digit organic growth, driven by IDEXX VetLab consumables (15% organic), premium instrument installed base growth (12%), and early adoption of the IDEXX inVue Dx analyzer (about 1,100 placements). The main watch items are the CEO transition, the pace of U.S. clinical visit recovery, operating expense growth that outpaces revenue, and the rising use of debt to fund buybacks, with the line of credit increasing to $530 million from $398 million at year-end 2025.

May 5, 2026
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Mar 26, 2026)

IDEXX Laboratories, Inc. (IDXX) filed an 8-K on March 26, 2026, to report the departure of Dr. Nimrata Hunt, Executive Vice President of Global Strategy and Commercial, effective April 13, 2026. This departure was a mutual agreement, and Dr. Hunt will provide advisory services until July 13, 2026. The company has entered into a separation agreement that outlines the terms of her exit and advisory role. Investors should note the financial implications of Dr. Hunt's departure, including a separation package totaling approximately $2.24 million in salary continuation and target bonuses, along with COBRA premium costs, transition assistance, and tax/financial planning reimbursements. The company is classifying this as a termination without cause. The agreement also includes standard clauses like general release of claims, non-disparagement, and ongoing adherence to restrictive covenants. This filing primarily addresses a significant executive transition and associated costs.

Mar 26, 2026
10-K

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2025

IDEXX Laboratories (IDXX) closed 2025 with record results: revenue rose 10.4% reported (9.6% organic) to $4.30 billion, and income from operations grew 20.5% to $1.36 billion, with operating margin expanding about 260 basis points to 31.6%. Net income reached $1.06 billion and diluted EPS was $13.08, up from $10.67 in 2024. Growth was led by the Companion Animal Group (CAG), where recurring diagnostic revenue (about 79% of consolidated revenue) rose 8.9%, driven by IDEXX VetLab consumables (+14.8%) and reference laboratory services (+6.6%). The new IDEXX inVue Dx cytology analyzer drove a 51.8% increase in instrument revenue. Gross margin improved to 61.8% and the installed base of premium instruments grew about 12%. The filing also flags headwinds that investors should weigh. Management expects U.S. same-store clinical visits to decline roughly 2% again in 2026, reflecting veterinary capacity constraints and macroeconomic pressure, and it projects a higher 2026 effective tax rate of about 21.3%. Operating cash flow was strong at $1.18 billion, but free cash flow after $125 million of capex was reduced by a roughly $80 million litigation payment. Capital returns were heavy: about $1.2 billion was spent repurchasing about 2.4 million shares, and the company guided to a further 1% to 2% reduction in diluted shares in 2026. Leverage remains modest, with a gross debt to Adjusted EBITDA ratio of 0.54x against a 3.5x covenant. Management also announced a planned CEO transition in May 2026. Risk factors emphasize concentration in a few key suppliers, including Ortho for Catalyst chemistry slides, along with rising competition from Mars-owned and Zoetis businesses, consolidation of corporate veterinary hospitals, and evolving AI, PFAS, and data-privacy regulation. Management reports that its internal controls over financial reporting were effective and that PwC issued an unqualified audit opinion.

Feb 20, 2026
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Feb 13, 2026)

IDEXX Laboratories, Inc. (IDXX) announced a change in its Board of Directors composition. Ms. M. Anne Szostak has notified the company of her intention to retire from the Board, effective immediately after the 2026 Annual Meeting of Stockholders on May 12, 2026. Her retirement is not due to any disagreements concerning the company's operations or policies, indicating a smooth transition. The company expressed gratitude for her significant contributions and leadership since 2012. The Board will reduce the size of the Class III directors upon Ms. Szostak's retirement. This reduction, however, will be offset by the previously announced appointment of Michael G. Erickson, PhD, as a Class II director, also effective immediately following the 2026 Annual Meeting. Investors should note that these changes are procedural and do not appear to reflect any underlying issues with the company's performance or governance.

Feb 13, 2026
8-K

IDEXX Laboratories 8-K Report, Financial Results (Feb 2, 2026)

IDEXX Laboratories reported strong fourth quarter 2025 results, with revenue of $1,091 million, up 14% as reported and 12% organically, and EPS of $3.08, up 18% as reported and 17% on a comparable basis. Growth was led by Companion Animal Group (CAG) Diagnostics recurring revenue, which rose 12% as reported and 10% organically, with international regions and U.S. both growing at or above sector levels. Operating margin expanded 150 basis points to 28.9%, and management cited over 1,900 IDEXX inVue Dx placements, a quarterly record for instrument placements. Full-year 2025 revenue reached $4,304 million (up 10% as reported and organically), and reported EPS of $13.08 rose 23%, though comparable EPS growth was 14% after adjusting for a prior-year litigation accrual and other items. For 2026, IDEXX issued initial guidance calling for revenue of $4,632 million to $4,720 million (7.6% to 9.6% reported growth, 7.0% to 9.0% organic) and EPS of $14.29 to $14.80 (9% to 13% reported growth, 10% to 14% comparable). Guidance assumes roughly 4% net price benefit in CAG Diagnostics recurring revenue, a targeted 40 to 90 basis points of reported operating margin improvement, and free cash flow conversion of 85% to 95% of net income. Investors will want to weigh strong momentum against the fact that the 2026 revenue outlook implies some deceleration from the 10% organic growth achieved in 2025, and that Q4 benefited from favorable currency and tax items. The filing is a routine furnishing of an earnings press release under Item 2.02 and is not deemed filed under the Exchange Act. It contains no material new contractual, legal, or governance events beyond the results and outlook themselves.

Feb 2, 2026
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Jan 13, 2026)

On January 13, 2026, IDEXX Laboratories announced a planned CEO succession. Jonathan (Jay) Mazelsky, President and CEO since 2019, will step down as CEO effective May 12, 2026, and move to Executive Chair of the Board. Michael (Mike) Erickson, PhD, currently EVP and General Manager of Global Point of Care Diagnostics and Telemedicine, will become President and CEO on that date and join the Board as a Class II Director. Mazelsky plans to retire from the company and the Board immediately after the May 2027 annual shareholder meeting, giving the two a roughly one-year overlap. Lawrence D. Kingsley, the current independent Non-Executive Chair, will become independent Lead Director on the Transition Date. The filing is largely a planned, orderly succession rather than a response to performance problems, and the company frames it as the outcome of a formal Board succession planning process. The filing does not disclose any change to guidance, financial results, or strategy. The main investor-relevant items are the compensation terms and the change-in-control protections. Erickson's base salary is $1,000,000 with a 120% target bonus, and he is expected to receive a 2026 long-term equity award with a target grant value of at least $7.8 million, split 50% stock options and 50% performance RSUs. Mazelsky's Executive Chair salary is $1,150,000, and he is expected to receive time-vesting RSUs with a target grant value of at least $8.275 million. Both agreements include severance and change-in-control provisions, which are standard for this type of transition. For investors, the key questions are whether Erickson's continuity as a long-serving insider supports execution on the company's innovation-driven growth strategy, and whether the overlap period with Mazelsky reduces transition risk. The filing gives no indication of execution risk, though investors should watch for the company's plans for the strategy and any changes to its operating priorities once Erickson takes over in May 2026.

Jan 13, 2026
8-K

IDEXX Laboratories 8-K Report, Material Agreement (Nov 13, 2025)

IDEXX LABORATORIES INC /DE (IDXX) filed an 8-K on November 12, 2025, detailing an amendment to its credit agreement. This amendment, specifically Amendment No. 2 to the Fourth Amended and Restated Credit Agreement, primarily extends the maturity dates for its revolving credit facility and introduces a new term loan facility. The revolving credit facility will now mature five years from the amendment's closing date, while the new term loan facility will mature three years from closing. This strategic move enhances the company's financial flexibility and extends its debt maturity profile. The total credit facility remains at $1.0 billion for the revolving line, with an additional $250 million for the term loan, and includes the option to incur up to an additional $250 million in incremental commitments. Borrowings can be used for general corporate purposes, providing management with resources for ongoing operations and potential strategic initiatives.

Nov 13, 2025
8-K

IDEXX Laboratories 8-K Report, Financial Results (Nov 3, 2025)

IDEXX Laboratories reported third quarter 2025 results on November 3, 2025, with revenue of $1,105 million, up 13% as reported and 12% organic. Growth was led by Companion Animal Group (CAG), which rose 14% as reported and 12% organic, and Livestock, Poultry and Dairy (LPD), which rose 17% as reported and 14% organic. CAG Diagnostics recurring revenue grew 11% as reported and 10% organic, with international regions up 18% reported and U.S. up 8%. Growth was supported by strong IDEXX VetLab consumables (+18% reported) and over 1,700 IDEXX inVue Dx placements, which drove capital instrument revenue up 74%. Profitability improved meaningfully. Diluted EPS was $3.40, up 21% as reported and 15% on a comparable basis, which excludes $0.17 of share-based compensation tax benefits and $0.02 of currency benefit. Gross margin rose 70 basis points to 61.8%, and operating margin expanded 100 basis points to 32.1% (120 basis points comparable). Operating expenses rose 12%, reflecting commercial, R&D, and incentive investments. Free cash flow for the quarter was $371 million, versus $192 million a year earlier. Management raised full-year 2025 guidance across the board. Revenue is now expected at $4,270–$4,300 million (9.6%–10.3% reported growth), EPS at $12.81–$13.01 (up $0.33 at the midpoint), and operating margin at 31.6%–31.8%. Investors should note that the EPS raise includes some non-operational items, including tax and share-count effects, and that the Company's share repurchases of about $979 million year-to-date have been funded partly by a higher credit facility balance of $455 million.

Nov 3, 2025
10-Q

IDEXX Laboratories Quarterly Report for Q3 Ended Sep 30, 2025

IDEXX Laboratories, Inc. reported strong financial results for the nine months ended September 30, 2025. Total revenue increased by 9.2% to $3.21 billion, driven by robust performance in its Companion Animal Group (CAG) segment, which saw a 9.3% revenue increase. The company demonstrated solid operational execution, with income from operations rising by 20.5% to $1.04 billion and net income growing by 20.8% to $811.3 million. Diluted EPS also saw a significant increase, reaching $9.99 for the nine-month period. The company's strategic focus on recurring revenue streams, particularly within its CAG Diagnostics recurring revenue category, continues to be a key driver of growth and profitability, with this segment showing a 7.8% increase. Financial health remains strong, with ample liquidity and a healthy balance sheet, supported by consistent operating cash flow generation. The company also continued its commitment to shareholder returns through active share repurchase programs. For the third quarter of 2025, IDEXX maintained its positive momentum, with total revenue up 13.3% year-over-year to $1.11 billion, and income from operations increasing by 16.8% to $354.8 million. The CAG segment once again led the growth, with a 13.5% revenue increase, bolstered by strong performance in IDEXX VetLab consumables and reference laboratory diagnostic services. Despite inflationary pressures and the impact of foreign currency fluctuations, IDEXX successfully expanded its gross profit margin and maintained disciplined operating expense management, leading to improved profitability. The company's outlook for the remainder of the year appears positive, with favorable currency impacts projected.

Nov 3, 2025
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Oct 7, 2025)

IDEXX Laboratories disclosed in an October 7, 2025 Form 8-K (Item 5.02) that its Board elected Karen Peacock as an independent Class I director, effective October 6, 2025. The Board expanded from ten to eleven directors and Class I seats from three to four to accommodate her. She joins the Compensation and Talent Committee and the Finance Committee, and is expected to stand for election at the 2027 annual meeting. The filing reports no related person transactions requiring disclosure. The event is governance-related rather than financial. The filing contains no earnings, guidance, or balance-sheet information. Compensation for Ms. Peacock matches the existing non-employee director program: a prorated Q4 2025 cash fee, and prorated annual equity grants (DSUs or RSUs and stock options) to be made December 1, 2025, covering service through the 2026 annual meeting. She may defer cash fees and RSUs under the Director Deferred Compensation Plan. Because the award values are prorated and the cash fee is standard, the financial impact on IDEXX is immaterial. The appointment is notable for its skills profile. Ms. Peacock is the former CEO of Intercom, a customer service and AI platform, and spent about 14 years at Intuit, including leading its Small Business division. She also serves as lead independent director at Dropbox. The company's press release frames her as bringing B2B SaaS and AI experience, which aligns with IDEXX's stated push into software and AI-enabled veterinary tools. Investors may view this as a signal of the board's emphasis on digital and software capabilities.

Oct 7, 2025
8-K

IDEXX Laboratories 8-K Report, Financial Results (Aug 4, 2025)

IDEXX Laboratories reported second quarter 2025 revenue of $1,109 million, up 11% as reported and 9% organic, with Companion Animal Group (CAG) growing 11% reported and 10% organic. CAG Diagnostics recurring revenue grew 9% reported and 7% organic, led by 15% reported growth in IDEXX VetLab consumables and record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx analyzers. Diluted EPS was $3.63, up 49% as reported but only 17% on a comparable basis, which strips out a $0.56 benefit from lapping the prior-year $61.5 million litigation accrual and a $0.07 discrete tax reserve release. Gross margin expanded 90 basis points to 62.6%, and operating margin rose to 33.6% (up 130 basis points on a comparable basis). Management raised its 2025 guidance. Revenue is now expected at $4,205 million to $4,280 million (7.7% to 9.7% reported growth, 7% to 9% organic), an increase of about $90 million at the midpoint, of which roughly $70 million reflects favorable foreign exchange. The EPS outlook rose to $12.40 to $12.76, a $0.40 increase at the midpoint that includes $0.22 from FX and $0.09 from higher share-based compensation benefits. Comparable operating margin expansion of 50 to 80 basis points was maintained, and the company is planning commercial expansion in select international regions in the second half. Balance sheet and cash flow warrant attention. Free cash flow for the first half was $359.6 million, versus $383.3 million a year earlier. Cash fell to $164.6 million, the line of credit rose to $579 million from $250 million at year-end 2024, and the company repurchased roughly $739 million of stock in the first six months. Investors should also note that the company will hold its 2025 Investor Day on August 14, 2025.

Aug 4, 2025
10-Q

IDEXX Laboratories Quarterly Report for Q2 Ended Jun 30, 2025

IDEXX LABORATORIES, INC. (IDXX) reported a strong second quarter for 2025, demonstrating robust revenue growth and improved profitability. Total revenue increased by 10.6% year-over-year to $1.11 billion for the three months ended June 30, 2025, driven by solid performance across its key segments, particularly the Companion Animal Group (CAG). This growth was fueled by strong recurring revenue from diagnostics, consumables, and services, along with a significant increase in instrument placements. The company's operational efficiency is evident in the expansion of its gross profit margin, which increased by 90 basis points to 62.6%, driven by higher volumes, price realization, and productivity improvements. While operating expenses saw an increase primarily in sales and marketing, a significant decrease in general and administrative expenses, due to a one-time litigation charge in the prior year, led to a substantial 41.4% increase in income from operations to $373.0 million. This performance highlights IDEXX's ability to grow its top line while managing costs effectively, presenting a positive financial outlook for investors.

Aug 4, 2025
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Jul 10, 2025)

IDEXX Laboratories (IDXX) filed an 8-K on July 10, 2025 to report that its Board of Directors elected Joseph L. (Jay) Hooley as an independent Class III Director, effective that same day. Mr. Hooley was also appointed to the Audit Committee and the Governance and Corporate Responsibility Committee. To seat him, the Board expanded from nine to ten directors and increased the Class III seats from three to four. He is expected to stand for stockholder election at the 2028 annual meeting. For investors, this is a routine governance event rather than a material change to operations or financial results. The filing discloses no related person transactions under Item 404(a) and reports no disagreements or other board-level concerns. Mr. Hooley's background is substantial: he previously served as Chair and CEO of State Street Corporation and is currently lead independent director of Exxon Mobil and a director of Aptiv PLC. His addition strengthens the Audit Committee's financial oversight experience. After his appointment, nine of the ten directors are independent, which the company highlights as a governance positive. Compensation is in line with other non-employee directors, with the Q3 2025 cash fee prorated and equity grants made on September 1, 2025, also prorated for his partial service year. The grant values are modest in the context of IDEXX's overall equity compensation. The company furnished the related press release as Exhibit 99.1 under Item 7.01/9.01, meaning it is not deemed filed for Exchange Act liability purposes.

Jul 10, 2025
8-K

IDEXX Laboratories 8-K Report, Bylaw Amendment (May 9, 2025)

IDEXX LABORATORIES INC /DE (IDXX) has filed an 8-K report detailing significant amendments to its corporate governance documents, effective May 7, 2025. The company has eliminated its Series A Junior Participating Preferred Stock, returning these shares to undesignated preferred stock status. More critically for investors, the company's Certificate of Incorporation and By-Laws have been amended to remove supermajority voting requirements and to allow for officer exculpation, aligning with recent Delaware law changes. These changes were approved by the Board of Directors and subsequently ratified by stockholders at the Annual Meeting held on May 7, 2025.

May 9, 2025
10-Q

IDEXX Laboratories Quarterly Report for Q1 Ended Mar 31, 2025

IDEXX Laboratories, Inc. reported a solid first quarter for 2025, with total revenue growing 3.6% to $998.4 million compared to the prior year. This growth was primarily driven by a 4.7% increase in organic revenue, demonstrating continued underlying business strength, particularly within the Companion Animal Group (CAG) segment. The company also maintained healthy profitability, with income from operations rising 5.9% to $316.5 million and a gross profit margin improvement to 62.4%. Significant stock repurchases were undertaken during the quarter, indicating a commitment to returning capital to shareholders, although this also contributed to a decrease in cash and cash equivalents. While the company navigated some headwinds, including foreign currency fluctuations which negatively impacted revenue growth by 1.2%, the overall financial performance appears robust. Management expects continued growth, supported by new business gains, customer retention, and strategic investments in product development. The company also successfully managed its debt levels, maintaining compliance with its leverage ratio covenants, and has sufficient liquidity to fund operations and growth initiatives for the foreseeable future.

May 1, 2025
8-K

IDEXX Laboratories 8-K Report, Financial Results (May 1, 2025)

IDEXX Laboratories reported first-quarter 2025 revenue of $998 million, up 4% as reported and 5% organically, with EPS of $2.96 (up 5% as reported, 7% comparable). Growth was led by IDEXX VetLab consumables (up 9% reported, 10% organic) and a 9% increase in its global premium instrument installed base, including over 300 IDEXX inVue Dx placements. Gross margin expanded 90 basis points to 62.4%, while operating margin was 31.7%, up 70 basis points as reported but down 10 basis points on a comparable basis after excluding a one-time litigation accrual benefit. Reference lab growth was essentially flat as reported, and rapid assay revenue declined 3%. The headline guidance change is a raise to 2025 revenue of $4,095-$4,210 million (about $40 million higher at midpoint), driven almost entirely by a weaker U.S. dollar; organic growth guidance of 6%-9% was maintained. Full-year EPS guidance was raised to $11.93-$12.43 (a $0.19 increase), of which $0.11 came from currency and $0.08 from the favorable resolution of a now-concluded litigation matter. Comparable EPS growth guidance of 8%-12% was unchanged, so underlying operating momentum was stable rather than improved. The quarter also featured the late-March launch of IDEXX Cancer Dx, a canine lymphoma early-detection panel in North American reference labs. Operating cash flow was $238 million and free cash flow $208 million, but the company spent about $401 million on share repurchases in the quarter, and cash fell to $164 million with the line of credit rising to $320 million. The litigation accrual was reduced by roughly $9 million and the judgment was paid in April 2025.

May 1, 2025
10-K

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2024

IDEXX Laboratories' FY2024 10-K shows a company still growing at a solid clip with strong profitability, though 2025 guidance points to a slower top line. Revenue rose 6.5% reported (6.4% organic) to $3.90 billion, driven mainly by price realization and recurring Companion Animal Group (CAG) diagnostics revenue, which made up about 80% of consolidated revenue. Gross margin expanded 120 basis points to 61.0%, and operating income grew 2.8% to $1.13 billion. Diluted EPS was $10.67, up from $10.06, and net income reached $887.9 million. Results were held back by a $61.5 million charge tied to an ongoing royalty litigation matter, which the company has now accrued at $89.0 million. Cash generation remained strong, with operating cash flow of $929.0 million. Management returned capital aggressively: $837.0 million in buybacks in 2024, with roughly $1.5 billion of repurchases planned for 2025. Cash fell to $288.3 million, and total debt is modest, with a gross debt to Adjusted EBITDA ratio of 0.65x and a net debt ratio of 0.44x, well inside the 3.5x covenant. Near-term maturities include a $250 million term loan due October 2025 and senior notes due in 2025 and 2026. Looking ahead, management expects U.S. same-store clinical visits to decline in 2025, reflecting sector capacity constraints and macroeconomic headwinds. Foreign exchange is also a meaningful drag, with about $80 million of expected revenue impact and $0.21 of EPS headwind at current rates, partly offset by hedging. The effective tax rate is projected to rise to about 21.5%. Overall, investors are weighing durable recurring revenue and strong capital returns against softer visit trends and a stronger dollar.

Feb 21, 2025
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Feb 14, 2025)

IDEXX Laboratories, Inc. (IDXX) has filed a Form 8-K reporting the immediate resignation of Dr. Asha Collins from its Board of Directors, effective February 13, 2025. The company explicitly states that Dr. Collins' departure was not due to any disagreements regarding the company's operations, policies, or practices. This event has resulted in a reduction of the Board's size from ten to nine directors. The company expressed gratitude for Dr. Collins' contributions during her time on the Board. While this filing does not contain financial results or strategic updates, the departure of a director, even under amicable circumstances, is a noteworthy event for investors. It may prompt questions about board composition, governance, and any potential implications for future decision-making. Investors should monitor future filings for any information regarding the replacement of Dr. Collins or changes in board committee memberships.

Feb 14, 2025
8-K

IDEXX Laboratories 8-K Report, Financial Results (Feb 3, 2025)

IDEXX Laboratories reported fourth quarter 2024 revenue of $954 million, up 6% both as reported and organically, led by Companion Animal Group (CAG) growth of 6%. CAG Diagnostics recurring revenue grew 6% reported and 7% organically, with IDEXX VetLab consumables up 12%. Q4 EPS was $2.62, up 13% as reported and 10% on a comparable basis, and operating margin expanded 20 basis points as reported (50 bps comparable). Full-year 2024 revenue reached $3,898 million (up 6%), but full-year reported EPS grew only 6% to $10.67 because of a $0.56 per-share charge from a discrete litigation accrual recorded in Q2 2024. Reported operating margin contracted 100 bps to 29.0%, though comparable margin expanded 60 bps. For 2025, IDEXX guided to revenue of $4,055 million to $4,170 million (4% to 7% reported, 6% to 9% organic) and EPS of $11.74 to $12.24 (10% to 15% reported, 8% to 12% comparable). Management targets 200 to 250 bps of reported operating margin improvement, including roughly 160 bps from lapping the 2024 litigation expense. Guidance assumes about $1.5 billion in share repurchases in 2025, equal to roughly 4% of current market capitalization, and a 2% to 3% reduction in average shares outstanding. Foreign currency is expected to reduce 2025 revenue growth by about 2 percentage points and EPS by about $0.21. The company also highlighted new product launches, including the IDEXX inVue Dx Cellular Analyzer, which began shipping in Q4 2024, and IDEXX Cancer Dx canine lymphoma screening, planned for late March 2025 in the U.S. and Canada. Cash flow remained strong, with 2024 free cash flow of $808 million, but cash fell to $288 million at year-end after $837 million of share repurchases. Investors will likely focus on whether the new products can sustain CAG Diagnostics recurring revenue growth, whether the margin recovery holds, and how the aggressive buyback program affects per-share value.

Feb 3, 2025
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Dec 12, 2024)

IDEXX LABORATORIES INC /DE (IDXX) announced on December 11, 2024, the adoption of a new Nonqualified Deferred Compensation Plan, effective December 6, 2024. This plan allows a select group of management and highly compensated employees to voluntarily defer a portion of their base salary, annual bonus, and Stock Units. The primary purpose of this plan is to provide tax-advantaged savings opportunities for key personnel, aligning with Section 409A of the Internal Revenue Code. While the company has no current intention to make discretionary contributions, the plan allows for such contributions in the future, with specific vesting conditions. Distributions can occur upon separation from service, specified dates, death, or unforeseen emergencies, with settlement typically in cash, except for Stock Unit deferrals which will be settled in company common stock. This initiative aims to enhance executive compensation and retention strategies by offering a flexible and tax-efficient way for participants to save for the future.

Dec 12, 2024
8-K

IDEXX Laboratories 8-K Report, Corporate Update (Dec 9, 2024)

On December 9, 2024, IDEXX Laboratories (NASDAQ: IDXX) disclosed that its Board's Finance Committee, on December 3, 2024, authorized an increase to the company's ongoing share repurchase program of up to five million additional shares of common stock. The authorization comes on top of the roughly 1.3 million shares that remained under prior Board authorizations as of December 3, 2024, bringing total available repurchase capacity to approximately 6.3 million shares before any repurchases under the new authorization are reflected. For investors, the key signal is management's and the Board's confidence in the company's capital position and valuation, as well as a commitment to returning capital to shareholders. Repurchases may be executed at management's discretion in the open market (including under Rule 10b5-1 plans) or in negotiated transactions, and the program has no expiration date. Because the filing does not specify a dollar amount, timing, or funding source, the actual impact on share count and earnings per share will depend on how aggressively management deploys the authorization. The filing is an Item 8.01 voluntary disclosure with no financial statements, guidance changes, or other material operational information. The company may suspend or discontinue the program at any time, so the authorization should be viewed as flexible capacity rather than a binding commitment to a specific level of buybacks.

Dec 9, 2024
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Nov 21, 2024)

IDEXX Laboratories (IDXX) announced a planned CFO transition in an 8-K filed November 21, 2024. Brian McKeon, Executive Vice President, Chief Financial Officer and Treasurer since January 2014 (and a Board member from 2003 to 2013), will retire effective June 1, 2025. He will step down as CFO, principal financial officer and principal accounting officer effective March 1, 2025, then serve as Executive Vice President and Special Advisor until his retirement to support a smooth handover. Oversight of the Water, Livestock, Poultry and Dairy and OPTI Medical businesses moves to Michael Lane, EVP and General Manager, Reference Laboratories and Information Technology, effective January 1, 2025. The Board named Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (CAG) Finance, as the successor CFO, effective March 1, 2025. Emerson, 41, has been with IDEXX since November 2015, has led CAG finance throughout that period, and has overseen corporate finance functions including investor relations, treasury, FP&A and financial reporting since March 2020. His compensation includes a $550,000 base salary, a fiscal 2025 target bonus of 75% of base, eligibility for annual equity grants, and a change-in-control agreement substantially mirroring McKeon's. The company stated there are no arrangements tied to his appointment and no related-party transactions requiring disclosure. For investors, the transition is largely an orderly, planned succession from an internal candidate with deep knowledge of the company's largest segment, which the CEO noted now generates more than 90% of revenue. The company also reaffirmed its full-year 2024 guidance issued October 31, 2024. The main watch items are execution during the handover period and whether the new CFO's priorities shift capital allocation or margin targets.

Nov 21, 2024
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Nov 12, 2024)

IDEXX LABORATORIES INC /DE (IDXX) filed an 8-K on November 11, 2024, reporting a significant change in its Board of Directors. Jonathan W. Ayers, a long-serving former executive and director, resigned from the Board and its finance committee effective November 8, 2024. The company stated that Mr. Ayers's departure was not due to any disagreements regarding company operations, policies, or practices. Mr. Ayers had a substantial tenure with IDXX, having served as Chairman, President, and CEO from 2002 to 2019, and as a non-employee director until his recent resignation. The Board expressed gratitude for his over two decades of service and contributions. Following his resignation, the size of the Board has been reduced from eleven to ten directors. The filing also includes his resignation letter as an exhibit.

Nov 12, 2024
8-K

IDEXX Laboratories 8-K Report, Material Agreement (Nov 6, 2024)

IDEXX Laboratories, Inc. (IDXX) has filed an 8-K report to disclose amendments to its material definitive agreements concerning the supply of dry slides for its veterinary chemistry analyzers. These amendments, effective October 31, 2024, extend the supply agreements with Ortho-Clinical Diagnostics, Inc. through the end of 2044 for both U.S. and European operations. The key changes involve a significant extension of the contract expiration dates and modifications to the pricing structures, including adjustments to volume tiers and associated pricing over the extended contract terms. These amendments are crucial for ensuring the continued supply of a critical component for IDEXX's diagnostic instruments, providing long-term operational stability and predictability.

Nov 6, 2024
8-K

IDEXX Laboratories 8-K Report, Financial Results (Oct 31, 2024)

IDEXX Laboratories reported third quarter 2024 results on October 31, 2024: revenue of $976 million, up 7% as reported and 6% organic, with CAG Diagnostics recurring revenue up 7% as reported and organic. Diluted EPS was $2.80, up 11% as reported and 12% on a comparable basis, and operating margin expanded 110 basis points to 31.2%. Growth was supported by double-digit growth in the premium installed base, international strength, and high-growth IDEXX VetLab consumables (+11%) and Water (+13%), while Livestock, Poultry and Dairy declined 3%. The key item for investors is the guidance cut. Full-year 2024 revenue guidance was lowered to $3,865 million to $3,890 million, a reduction of $38 million at the midpoint (about 1%), and organic growth guidance was reduced to 5.3% to 6.0%. Management attributed the change to macro and sector conditions that are constraining pet owner visits and demand at U.S. veterinary clinics. Full-year EPS guidance was narrowed to $10.37 to $10.53, which keeps the midpoint unchanged, and the operating margin outlook of 28.7% to 29.0% was maintained. The quarter also reflects a large one-time charge. In the second quarter, the company recorded a $61.5 million discrete litigation accrual related to alleged underpayment of royalties under an expired patent license, bringing the total accrual to $89.0 million. This is a roughly $0.56 per-share hit to 2024 EPS and about 160 basis points of reported operating margin. Management also highlighted nearly 700 pre-orders for the inVue Dx Cellular Analyzer, which begins shipping in the fourth quarter. Free cash flow for the first nine months was $575 million, and the company repurchased $591 million of stock during that period.

Oct 31, 2024
10-Q

IDEXX Laboratories Quarterly Report for Q3 Ended Sep 30, 2024

IDEXX Laboratories, Inc. reported strong third-quarter results, demonstrating robust revenue growth driven by its core Companion Animal Group (CAG) segment. Total revenue increased by 6.6% year-over-year to $975.5 million, with organic revenue growing by 6.1%, highlighting the company's ability to drive growth through a combination of price realization and volume increases across its diagnostic consumables and services. The company maintained healthy profitability, with gross profit margin improving to 61.1% and operating income rising by 10.4% to $303.9 million. This financial performance was supported by effective cost management and favorable business mix, despite ongoing inflationary pressures. IDEXX also continues to execute its capital allocation strategy, with significant share repurchases and investments in growth, while maintaining a strong liquidity position and compliance with financial covenants.

Oct 31, 2024
8-K

IDEXX Laboratories 8-K/A Report, Financial Results (Oct 31, 2024)

IDEXX Laboratories filed Amendment No. 1 to its October 31, 2024 Form 8-K solely to correct one figure in its third-quarter earnings release: the projected full-year 2024 comparable operating margin expansion is now 30 to 60 basis points, down from the originally printed 70 to 100 basis points. The correction is confined to that range; the rest of the release, including the revenue, EPS, and cash flow outlook, is unchanged. Investors should treat the corrected 30 to 60 basis point figure as the operative guidance, since the original press release overstated it. The corrected range matches the comparable margin expansion shown in the outlook table, so the original printed range was an inconsistency rather than a change in management's view. The underlying quarter was solid. Revenue rose 7% as reported and 6% organic to $976 million, with CAG Diagnostics recurring revenue up 7%, international recurring revenue up double digits, and Water up 13%. EPS was $2.80, up 11% as reported and 12% on a comparable basis, and reported operating margin expanded 110 basis points to 31.2%. Management did cut 2024 revenue guidance by about $38 million at the midpoint, citing softer U.S. clinic visit and pet owner demand, while holding the EPS midpoint steady at $10.37 to $10.53. The main concerns for investors are demand trends in U.S. veterinary clinics and the $61.5 million second-quarter litigation accrual, which takes the total accrual on the royalty dispute to $89.0 million. That charge drove a roughly $0.56 per share hit to 2024 EPS and about 160 basis points of reported margin impact. The amendment does not change any of these figures.

Oct 31, 2024
10-Q

IDEXX Laboratories Quarterly Report for Q2 Ended Jun 30, 2024

IDEXX Laboratories, Inc. reported solid revenue growth for the second quarter of 2024, driven primarily by its Companion Animal Group (CAG) segment, which saw increases in diagnostics recurring revenue, supported by price realization and volume growth. Overall revenue for the quarter increased by 6.4% year-over-year to $1.004 billion. While operating income saw a decline of 10.9% to $263.8 million, this was largely due to a significant $61.5 million expense related to an ongoing litigation matter. Excluding this one-time charge, the company demonstrated continued operational strength and profitability. The company's balance sheet remains robust, with total assets growing to $3.41 billion. While cash and cash equivalents decreased slightly to $401.6 million from $453.9 million at the end of 2023, this was primarily due to strategic uses of cash, including significant share repurchases totaling $370.3 million in the first six months of 2024. The company maintains substantial liquidity with $998.5 million in unused borrowing capacity under its credit facility, indicating strong financial flexibility. Investors should note the ongoing litigation accrual as a significant factor influencing near-term profitability.

Aug 6, 2024
8-K

IDEXX Laboratories 8-K Report, Financial Results (Aug 6, 2024)

IDEXX Laboratories reported second quarter 2024 revenue of $1,004 million, up 6% as reported and 7% organic, led by Companion Animal Group (CAG) growth of 6% reported and 7% organic. CAG Diagnostics recurring revenue grew 6% reported and 7% organic, with international regions up 8% reported and 10% organic and U.S. up 5%. Operating indicators were solid: record second quarter premium instrument placements, 11% growth in the global premium installed base, and gross margin of 61.7% (up 100 bps as reported). Water revenue rose 9% reported and 10% organic, while LPD grew 1% reported and 3% organic. The headline issue is a $61.5 million discrete expense accrual (about $0.56 per share) for an ongoing litigation matter involving alleged underpayment of royalties from 2004 through 2017 under an expired patent license. This pushed reported Q2 diluted EPS down 9% to $2.44 and operating margin down 510 bps to 26.3%. Excluding the charge, comparable EPS rose 15% to $3.02 and comparable operating margin expanded 110 bps to 32.4%. The company's total accrual for the matter is now $89.0 million, and the actual loss could be higher or lower. Management lowered its 2024 revenue guidance to $3,885-$3,945 million (6.2%-7.8% growth, organic and reported) from $3,895-$3,965 million, citing recent U.S. clinical visit trends. The reported EPS outlook was cut to $10.31-$10.59 from $10.82-$11.20, a $0.56 midpoint reduction driven entirely by the litigation accrual, while comparable EPS growth guidance of 9%-12% was maintained. Investors will likely focus on the sustainability of U.S. clinical visit trends and on the Investor Day scheduled for August 15, 2024.

Aug 6, 2024
8-K

IDEXX Laboratories 8-K Report, Executive Changes (May 10, 2024)

IDEXX Laboratories, Inc. (IDXX) filed an 8-K report on May 9, 2024, detailing two primary events: a consulting agreement with a former executive and the results of its 2024 annual shareholder meeting. Effective May 7, 2024, James F. Polewaczyk, formerly an Executive Vice President who retired on April 1, 2024, entered into a one-year consulting agreement. Under this agreement, Mr. Polewaczyk will provide coaching and professional development support to select employees for a fee of $25,000 per month. The annual meeting, held on May 6, 2024, saw shareholders approve all presented proposals. Key outcomes include the election of four Class I directors, the ratification of PricewaterhouseCoopers LLP as the independent registered accounting firm, and an advisory vote to approve executive compensation. Additionally, a shareholder proposal regarding simple majority vote was put to a vote and was approved by a majority of shareholders.

May 10, 2024
8-K

IDEXX Laboratories 8-K Report, Financial Results (May 1, 2024)

IDEXX Laboratories reported first-quarter 2024 revenue of $964 million, up 7% both as reported and organically, with EPS of $2.81, up 10% as reported and 9% on a comparable basis. Growth was led by Companion Animal Group (CAG) revenue up 7%, with CAG Diagnostics recurring revenue also up 7%. Water revenue rose 11%, while Livestock, Poultry and Dairy (LPD) declined 3%. Gross margin expanded 120 basis points to 61.5%, but operating margin slipped 10 basis points to 31.0% because the prior-year quarter benefited from a customer contract resolution payment (about 180 basis points of headwind). Operating expenses rose 12%, driven by higher R&D tied to the innovation agenda. Installed base of global premium instruments grew 11%, a key indicator of future recurring consumables revenue. Management updated 2024 revenue guidance to $3,895-$3,965 million (6.5%-8.5% reported growth, 7%-9% organic), lowering the high end of organic growth by about 1 point to reflect moderating U.S. clinical visit trends. The guidance also absorbs a roughly $35 million negative impact from a stronger U.S. dollar. EPS guidance was trimmed to $10.82-$11.20 from $10.84-$11.33 at the midpoint, a reduction of about $0.08, mainly from roughly $0.11 of FX headwind. Operating margin guidance of 30.2%-30.7% was maintained. Investors will likely focus on whether the softer U.S. clinical visit trend persists and on the durability of the premium instrument placement growth that underpins recurring revenue. Cash generation remained solid: operating cash flow was $198.6 million and free cash flow was $168.3 million in the quarter. The company repurchased about $155 million of stock in the open market and spent $77 million on an acquisition of a software and data platform business. Cash fell to $397 million at quarter-end, and the balance sheet shows a $250 million line of credit drawn and roughly $696 million in long-term debt including the current portion.

May 1, 2024
10-Q

IDEXX Laboratories Quarterly Report for Q1 Ended Mar 31, 2024

IDEXX Laboratories, Inc. reported solid financial results for the first quarter of 2024, with total revenue reaching $964.1 million, a 7.1% increase year-over-year. This growth was primarily driven by its core Companion Animal Group (CAG) segment, which saw a 7.5% revenue increase, largely due to higher recurring revenue from diagnostics, consumables, and veterinary software and services. The company also demonstrated improved profitability, with gross profit rising 9.2% and income from operations increasing 6.6% to $299 million, reflecting an expanded gross margin of 61.5% compared to 60.3% in the prior year, aided by favorable sales mix and pricing. While the company continues to invest in growth, evidenced by a rise in R&D and G&A expenses, its financial position remains strong. Net income increased by 10.1% to $235.6 million, resulting in diluted EPS of $2.81, up from $2.55 in the prior year. The company also maintained a healthy liquidity position, with $397.4 million in cash and cash equivalents and significant borrowing availability under its credit facility. Notably, IDEXX repurchased $154.8 million of its common stock during the quarter, signaling confidence and a commitment to returning value to shareholders. The company expects continued growth, though it acknowledges potential headwinds from macroeconomic conditions and foreign currency fluctuations.

May 1, 2024
10-K

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2023

IDEXX Laboratories' FY2023 10-K shows a strong year driven by pricing and recurring diagnostic revenue. Total revenue rose 8.7% reported (8.8% organic) to $3.66 billion, with Companion Animal Group (CAG) growing 9.6% to $3.35 billion and recurring CAG Diagnostics revenue reaching $2.94 billion, about 80% of consolidated revenue. Gross margin expanded 30 bps to 59.8%, and operating income rose 22.1% to $1.10 billion (30.0% of revenue), helped by a $16 million customer contract resolution gain and lower R&D after a prior-year $84 million technology license charge. Net income was $845 million, and diluted EPS was $10.06, up from $8.03. The balance sheet and cash flow improved meaningfully. Operating cash flow was $906.5 million, up from $543.0 million, and cash ended at $453.9 million versus $112.5 million a year earlier. Gross debt to Adjusted EBITDA was 0.74x and net debt to Adjusted EBITDA was 0.39x, well inside the 3.5x covenant. The company repurchased only $71.9 million of stock in 2023, versus $819.7 million in 2022, and it has never paid a cash dividend. Management's 2024 outlook includes a projected effective tax rate of about 22%, capital expenditures of about $180 million, and an approximately $77 million acquisition closed on February 1, 2024. Key risks flagged in the filing include intensifying competition, consolidation of veterinary practices into corporate groups and buying consortiums, sole-source supplier dependence (notably Ortho for chemistry slides), AI-related regulatory and reputational exposure, and a pending state supreme court ruling on a royalty lawsuit with a $50 million claim against which $27.5 million has been accrued. U.S. same-store clinical visits declined about 0.5% in 2023, so growth relied on pricing and diagnostic utilization rather than visit volume.

Feb 22, 2024
8-K

IDEXX Laboratories 8-K Report, Financial Results (Feb 5, 2024)

IDEXX Laboratories reported fourth quarter and full year 2023 results on February 5, 2024, closing a year of strong organic growth and margin expansion. Q4 revenue was $902 million, up 9% as reported and 8% organically, with Companion Animal Group (CAG) growing 10% reported and 9% organically. CAG Diagnostics recurring revenue grew 11% reported and 10% organically, led by IDEXX VetLab consumables (+14% reported, +13% organic) on the back of 11% expansion of the global premium instrument installed base. Q4 EPS was $2.32, up 13% as reported and 17% on a comparable basis. Full-year 2023 revenue reached $3,661 million (+9% reported and organic), and EPS was $10.06 (+25% reported, +29% comparable). Operating margin expanded 330 basis points as reported to 30.0%, though this was flattered by a $80 million in-license of technology in 2022 and a $16 million customer contract resolution in 2023, with the comparable benefit of roughly 280 basis points from these discrete items. For 2024, management guided to revenue of $3,930 million to $4,040 million, implying reported growth of 7.5% to 10.5% and organic growth of 7% to 10%. CAG Diagnostics recurring revenue is expected to grow 7.5% to 10.5%, assuming an estimated 5% benefit from net price improvement. EPS guidance is $10.84 to $11.33, representing 8% to 13% growth, though this includes roughly a 2% headwind from lapping the 2023 customer contract resolution. Operating margin is projected at 30.2% to 30.7%, a 20 to 70 basis point expansion net of a roughly 40 basis point drag from the lapping effect. Management expects operating cash flow of 110% to 115% of net income, free cash flow of 90% to 95% of net income, and capital expenditures of about $180 million. Investors should weigh the strong underlying demand and pricing power in consumables and the recurring revenue base against the normalization of 2023 one-time benefits, which makes the 2024 EPS growth optically lower than the 2023 headline. Balance sheet strength improved markedly, with cash rising to $454 million and the credit facility balance falling to $250 million from $579 million a year earlier.

Feb 5, 2024
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Dec 7, 2023)

IDEXX Laboratories, Inc. (IDXX) announced on December 5, 2023, that its Executive Vice President and Chief Commercial Officer, James F. Polewaczyk, will retire effective April 1, 2024. Mr. Polewaczyk has served the company in leadership capacities for over 17 years, contributing significantly to its commercial operations and growth. This departure marks the end of a long tenure for a key executive. Investors will likely want to understand the succession plan for this critical role and how Mr. Polewaczyk's departure might impact the company's commercial strategy and execution moving forward. While the filing does not provide details on a successor, it indicates a planned transition, allowing time for leadership to address this change.

Dec 7, 2023
10-Q

IDEXX Laboratories Quarterly Report for Q3 Ended Sep 30, 2023

IDEXX Laboratories Inc. (IDXX) reported strong financial results for the nine months ended September 30, 2023, with total revenue increasing by 8.7% to $2.76 billion and net income attributable to stockholders rising by 28.3% to $650.5 million, or $7.75 per diluted share. The Companion Animal Group (CAG) segment remains the primary revenue driver, showing robust growth across its recurring revenue streams, including consumables, diagnostics, and software services. The company also demonstrated solid cash flow generation, with operating activities providing $656.7 million, enabling significant debt reduction and strategic investments. Despite a challenging macroeconomic environment, IDEXX's diversified business model and focus on recurring revenue streams have proven resilient. The company successfully managed operational costs, leading to improved gross profit margins and overall profitability. While international revenue growth showed some moderation, the U.S. market remained a strong performer. Looking ahead, IDEXX is well-positioned to continue its growth trajectory, supported by its strong market position, ongoing innovation, and disciplined capital allocation.

Nov 1, 2023
8-K

IDEXX Laboratories 8-K Report, Financial Results (Nov 1, 2023)

IDEXX Laboratories reported third quarter 2023 results on November 1, 2023, with revenue of $916 million, up 9% as reported and 8% organically. Growth was led by Companion Animal Group (CAG) Diagnostics recurring revenue, which rose 10% reported and 9% organically, supported by an 11% year-over-year increase in the global premium instrument installed base. Diluted EPS was $2.53, up 18% as reported and 16% on a comparable basis, and operating margin expanded 100 basis points to 30.1% (140 basis points comparable). The company also noted continued headwinds to clinical visit growth globally and a stronger U.S. dollar. Management updated 2023 guidance. Revenue growth is now expected at 7.9%-8.4% as reported (8.3%-8.8% organic), at the lower end of the prior range, and reported revenue was trimmed by $20 million for foreign exchange. The reported operating margin outlook was raised to 29.6%-29.8%, and EPS guidance was set at $9.74-$9.90, with the midpoint raised by $0.05. The EPS range includes roughly 12 percentage points of growth from a one-time customer contract resolution payment in Q1 2023 and the lapping of 2022 R&D investments, so underlying growth is lower than the headline figure. Currency is now expected to be a $0.25 per share headwind for the full year. From an investor standpoint, the quarter reflects solid organic growth, strong instrument placements, and margin expansion, with the main caveats being softer clinical visit trends, FX pressure, and the non-recurring benefits embedded in the EPS guidance. Free cash flow was $238 million in the quarter and $556 million year-to-date, and the company repurchased only $35 million of stock in the nine-month period, far below the prior year's $742 million open-market buyback.

Nov 1, 2023
10-Q

IDEXX Laboratories Quarterly Report for Q2 Ended Jun 30, 2023

IDEXX Laboratories, Inc. reported solid financial results for the second quarter of 2023, demonstrating robust revenue and income growth. Total revenue increased by 9.7% year-over-year to $943.6 million, driven primarily by strong performance in the Companion Animal Group (CAG) segment, which saw a 10.5% increase in revenue. This growth was fueled by recurring diagnostics revenue, higher realized prices globally, and increased volumes in the U.S. Net income attributable to IDEXX stockholders grew significantly by 69.9% to $224.2 million, or $2.67 per diluted share. This substantial increase reflects improved gross margins, driven by pricing strategies and operational efficiencies, as well as a significant decrease in research and development expenses compared to the prior year's acquisition-related costs. The company maintained a strong balance sheet with increased cash and cash equivalents and a healthy liquidity position, underscored by a significant available borrowing capacity under its credit facility.

Aug 1, 2023
8-K

IDEXX Laboratories 8-K Report, Financial Results (Aug 1, 2023)

IDEXX Laboratories reported second quarter 2023 results on August 1, 2023, with revenue of $944 million, up 10% both as reported and organically. Growth was led by the Companion Animal Group (CAG), which rose 11%, and CAG Diagnostics recurring revenue, which grew 11% as reported and 12% organically. Management highlighted record second-quarter global premium instrument placements and 11% growth in the global premium instrument installed base. Diluted EPS was $2.67, up 71% as reported and 77% on a comparable basis. Roughly 54 points of that EPS growth came from lapping discrete 2022 R&D investments, so the underlying improvement is more modest than the headline figure suggests. Profitability improved sharply. Gross margin reached 60.7%, up 100 basis points as reported and 160 basis points comparably, and operating margin rose to 31.4% from 20.8% a year earlier. Operating expenses fell 17%, though that decline is flattered by the prior-year R&D comparison. Free cash flow for the first half was $317 million, compared with $119 million in the prior-year period. Total debt fell as the line of credit was reduced from $579 million at year-end 2022 to $264 million at June 30, 2023. For full-year 2023, IDEXX raised its EPS outlook to $9.64–$9.90 and narrowed its revenue guidance to $3,660–$3,715 million, implying 8.5%–10% growth. The EPS raise reflects operating improvements, a one-time customer contract resolution payment in Q1 2023, and the lapping of 2022 R&D spending. Management also cited a roughly $0.21 per share foreign exchange headwind, mainly from lapping 2022 hedge gains. An Investor Day was scheduled for August 10, 2023.

Aug 1, 2023
8-K

IDEXX Laboratories 8-K Report, Executive Changes (Jul 12, 2023)

IDEXX Laboratories filed an 8-K on July 12, 2023 to disclose the July 11, 2023 board election of Irene Chang Britt as an independent Class I Director. The board expanded from ten to eleven directors (Class I from three to four) to accommodate her seat. She was also appointed to the Audit Committee and the Compensation and Talent Committee, effective immediately. She is expected to stand for election by stockholders at the 2024 annual meeting. The filing reports no related person transactions requiring disclosure under Item 404(a) of Regulation S-K. The filing is a governance event rather than a financial one, and it contains no financial results, guidance, or material changes to operations. Ms. Chang Britt will receive the standard non-employee director package, reflecting the May 2023 increase in the annual cash retainer from $80,000 to $90,000 and the annual equity award from $230,000 to $250,000, split evenly between full-value awards and stock options. Her cash fees for Q3 2023 will be prorated, and her equity grants, also prorated, are scheduled for September 1, 2023. The compensation changes are modest in the context of a company of IDEXX's size. For investors, the appointment adds a director with significant consumer-products and public-company board experience, including prior senior roles at Campbell Soup Company and current board seats at Brighthouse Financial and Victoria's Secret & Co. Her placement on the Audit and Compensation committees is the most relevant detail for governance-focused investors. The announcement is best viewed as routine board refreshment with no direct near-term impact on IDEXX's fundamentals.

Jul 12, 2023
8-K

IDEXX Laboratories 8-K Report, Shareholder Vote Results (May 19, 2023)

IDEXX Laboratories, Inc. (IDXX) filed an 8-K report detailing the results of its 2023 Annual Meeting of Shareholders, held on May 17, 2023. The primary purpose of this filing was to report the voting outcomes on several key proposals. Investors should note that all proposed items, including the election of three Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and advisory votes on executive compensation and its frequency, received majority shareholder approval. The election of directors Daniel M. Junius, Lawrence D. Kingsley, and Sophie V. Vandebroek was successful, with significant "For" votes compared to "Against" and "Abstain" votes, ensuring continued board leadership. Shareholders also overwhelmingly ratified the appointment of PricewaterhouseCoopers LLP, indicating confidence in their financial oversight. Furthermore, the advisory vote to approve executive compensation passed, and the company will hold an advisory vote on executive compensation annually, as decided by the shareholders.

May 19, 2023
10-Q

IDEXX Laboratories Quarterly Report for Q1 Ended Mar 31, 2023

IDEXX Laboratories, Inc. (IDXX) reported solid financial results for the first quarter of 2023, demonstrating continued growth driven by its Companion Animal Group (CAG) segment. Total revenue increased by 7.6% year-over-year to $900.2 million, with organic revenue growth of 9.8%, reflecting strong performance in recurring revenue, price increases, and software/service offerings. Despite some headwinds in the LPD and Other segments, the company's overall profitability improved, with a 12.9% increase in income from operations to $280.4 million. The company also showed progress in managing its financial resources, evidenced by a significant increase in operating cash flow and a reduction in credit facility borrowings. While facing inflationary pressures impacting cost of revenue and operating expenses, IDEXX maintained its focus on strategic investments in growth initiatives, particularly within its core CAG segment. The company's financial position remains strong, with ample liquidity and a conservative leverage ratio, positioning it well for future growth and resilience.

May 2, 2023
8-K

IDEXX Laboratories 8-K Report, Financial Results (May 2, 2023)

IDEXX Laboratories reported first quarter 2023 revenue of $900 million, up 8% as reported and 10% organically, with Companion Animal Group (CAG) Diagnostics recurring revenue growing 9% reported and 12% organically. U.S. CAG Diagnostics organic recurring revenue rose 14%, and management cited record first-quarter global premium instrument placements and an 11% annual increase in the global premium instrument installed base. Growth was broad-based across VetLab consumables (+12% organic), reference laboratory services (+11% organic), rapid assays (+12% organic), and veterinary software and imaging (+14% organic). Water grew 7% reported, while Livestock, Poultry and Dairy (LPD) declined 5% reported (-2% organic). Profitability was strong. Diluted EPS was $2.55, up 12% as reported and 18% on a comparable basis, though results were flattered by a $16 million one-time customer contract resolution payment. Gross margin expanded 70 basis points to 60.3%, and operating margin rose 150 basis points to 31.1% (210 basis points on a comparable basis). Operating expenses grew 5% reported, driven by higher sales and marketing spending as in-person sales meetings resumed and by R&D investment. Net income was $214 million, and free cash flow was $144 million, versus $83 million a year earlier. Full-year 2023 guidance was modestly raised at the low end. Revenue is now expected at $3,615 million to $3,700 million (7.5%-10% growth, reported and organic), with the reported revenue range lifted by about $10 million on favorable FX. The operating margin outlook was refined to 29.0%-29.5%, including roughly 60 basis points of FX headwind, and EPS guidance is $9.33-$9.75, with the low end raised by $0.06. Management noted that about 12 percentage points of combined EPS growth benefit comes from the Q1 contract resolution payment and from lapping discrete 2022 R&D investments, so underlying growth is lower than headline figures suggest.

May 2, 2023
10-K

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2022

IDEXX Laboratories' FY2022 10-K shows a company that grew revenue 4.7% reported (7.4% organic) to $3.37 billion, with diluted EPS of $8.03, down from $8.60 in 2021. The decline in earnings reflects a $65 million in-process R&D charge from two IP licensing arrangements, higher R&D spend overall (R&D rose to 7.6% of revenue from 5.0%), a higher effective tax rate of 21.0% versus 17.5%, and a 3.4% currency headwind to reported revenue growth. Operating income fell 3.6% to $898.8 million, and operating margin compressed from 29.0% to 26.7%. The Companion Animal Group (CAG) drives the business, generating about 91% of revenue, with recurring diagnostic revenue of roughly 79% of consolidated revenue. Growth was led by price realization and higher VetLab consumable and reference laboratory volumes, while Water grew 6.3% and LPD declined 9.8% on weaker China swine testing. Cash flow from operations fell to $543 million from $756 million, driven by heavier inventory build and other working-capital changes, and the company spent $820 million on share repurchases, funded in part by a $432 million increase in credit facility borrowings. Leverage rose meaningfully: total debt including the revolver reached about $1.35 billion, a gross debt to Adjusted EBITDA ratio of 1.27x and net leverage of 1.17x, well inside the 3.5x covenant. Management guides to a roughly 22% effective tax rate for 2023, a $180 million capex plan, and a stronger dollar headwind of about $0.23 per share in 2023. A pending $27.5 million accrual related to an ongoing royalty lawsuit and the possible impact of the Maine PFAS rules are the main contingent items flagged for investors.

Feb 16, 2023